Detection of loss of heterozygosity in patients with urinary bladder carcinoma: Neoplastic tissue vs. urine sediment cells

Central European Journal of Urology

Volumn 64, Issue 3, 2011, Pages 163-167

  Traczyk, Magdalena ^a   Borkowska, Edyta ^a   Jȩdrzejczyk, Adam ^b   Pietrusiński, Michał ^a   Rozniecki, Marek ^c   Marks, Piotr ^b   Kałuzewski, Bogdan ^a  

^a Medical University of oadza   (Poland)

^b Department of Urology   (Poland)

^c The Clinic of Urology   (Poland)

Author keywords

Bladder cancer; CDKN2A ARF; LOH; Loss of heterozygosity; RB1; TP53

Indexed keywords

EID: 80052413622     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2011.03.art16     Document Type: Article

References (26)

1. Cheng L, Zhang S, MacLennan G, et al: Bladder Cancer: translating molecular genetics insights into clinical practice. Hum Pathol 2011; 42 (4): 455-481.
2. Wojciechowska U, Didkowska J, Zatoński W: Nowotwory złośliwe w Polsce w 2006 roku. The National Register of Neoplasms, The M. Skłodowska-Curie Centre of Oncology; Warsaw 2008.
3. National Cancer Institute: Priorities of the Kidney/Bladder Cancers Progress Review Group. http://planning.cancer.gov/pdfprgreports/2002kidneyreport. pdf (03.03.2009).
4. Pasin E, Josephson D, Mitra A, Cote R, Stein J: Superficial bladder cancer: An update on etiology, molecular development, classification and natural history. Rev Urol 2008; 10 (1): 31-43.
5. Colombel M, Soloway M, Akaza H, et al: Epidemiology, Staging, Grading and Risk Stratification of Bladder Cancer. Eur Urol Suppl 2008; 7: 618-626.
6. Zlotta AR, Cohen SM, Dinney C, Droller M, et al: BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. Urol Oncol. 2010; 28 (3): 329-333.
7. Badalament RA, Schervish EW: Rak pe{ogonek}cherza moczowego. Współczesne metody rozpoznawania i leczenia. [Bladder cancer. Current methods of diagnosis and treatment]. Medycyna po dyplomie 1997; 6 (2): 167-174.
8. Crawford JM: The origins of bladder cancer. Lab Invest 2008; 88 (7): 686-693.
9. Jacobs B, Lee C, Montie J: Bladder cancer in 2010. How far we come. CA Cancer J Clin 2010; 60: 244-272.
10. Goebell PJ, Knowles MA: Bladder cancer or bladder cancer? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28 (4): 409-28.
11. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006; 27 (3): 361-73.
12. Berggren P: Molecular changes in the tumor suppressors genes p53 and CDKN2A/ARF in human urine bladder cancer, Stockholm, 2002, chapt. 6, pp. 23-28.
13. Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol pahtol 2001; 54: 215-221.
14. Turyn J, Matuszewski M, Schlichtholz B: Genomic instability analysis of urine sediment versus tumor tissue in transitional cell carcinoma of the urine bladder. Oncol Rep 2006; 15: 259-265.
15. Utting M, Werner W, Dahse R, Schubert J, Junker K: Microsatellite analysis of free tumor DNA in urine, serum and plasma of patients: A minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002; 8: 35-40.
16. Knowles MA, Elder P, Williamson M, Cairns J, Shaw M, Law M: Allotype of human bladder cancer. Cancer Res 1994; 54: 531-583.
17. Erbersdobler A, Friedrich M, Schwaibold H, Huland H: Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urine bladder. Oncol Res 1998; 10 (8): 415-420.
18. Smeds J, Berggren P, Ma X, Xu Z, et al: Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) and p53 genes are major targets for inactivation. Carcinogenesis 2002; 23 (4): 645-55.
19. Berggren P, Kumar R, Sakano S, et al: Detecting Homozygous Deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) Gene in Urinary Bladder Cancer Using Real-Time Quantitative PCR. Clin Cancer Res 2003; 9: 235-242.
20. Vousden K, Lane D: p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8 (4): 275-283.
21. Michalski W, Demkow T: Przegla{ogonek}d wybranych markerów diagnostycznych i prognostycznych u chorych na raka pe{ogonek}cherza moczowego. [A review of selected diagnostic and prognostic markers in patients with bladder cancer]. Urol Pol 2007; 60: 2.
22. Mao L, Schoenberg MP, Scicchitano M, et al: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659-662.
23. Dal Canto M, Bartoletti R, Travaglini F, et al: Molecular urine sediment analysis in patient with transitional cell bladder carcinoma. Anticancer Res 2003; 23 (6D): 5095-5100.
24. Little B, Hughes A, Young M, O'Brien A: Use of polymerase chain reaction analysis of urine DNA to detect bladder carcinoma. Urol Oncol 2005; 23 (2): 102-107.
25. Sourvinos G, Kazanis I, Delekas D, Cranidis A, Spandidos D: Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J Urol 2001; 165: 249-252.
26. Shigyo M, Sugano K, Taniguchi T, et al: Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end8 single-strand DNA conformation polymorphism. Int J Cancer 1998; 78 (4): 425-429.